BridgeBio doses first patient in Phase 3b/4 acoramidis heart study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. QCOM
7. IRT
8. ASO
9. LAES
10. UNFI

Go back to BridgeBio doses first patient in Phase 3b/4 acoramidis heart study
(NASDAQ: BBIO) Delayed: 76.11 +1.35 (1.81%)
Previous Close $74.76    52 Week High $ 
Open $73.63    52 Week Low $ 
Day High $76.53    P/E N/A 
Day Low $73.47    EPS $ 
Volume 812,794